Susan E. Siegel
Susan (Sue) E. Siegel was elected as a director of Align in May 2017. Ms. Siegel has driven game-changing ideas and powered companies that advance industries and improve lives for more than three decades. Most recently, as GE’s Chief Innovation Officer and CEO of GE Ventures, Ms. Siegel oversaw investment in startups, created and scaled new companies, and commercialized GE’s intellectual property. She also led strategy planning and oversaw the global marketing function.
Before joining GE, Ms. Siegel was a Silicon Valley-based healthcare and life sciences VC. Prior to becoming a venture capitalist, she led Affymetrix as President and a board member, where she drove the company’s transformation from a pre-revenue startup to a global, multi-billion-dollar market cap genomics leader. Ms. Siegel also held executive leadership roles at Bio-Rad, DuPont and Amersham after transitioning to a corporate career from early work in molecular biology and biochemistry.
She also serves on the boards of Illumina (ILMN), Nevro Corp. (NVRO), MIT’s The Engine, and the Kaiser Family Foundation. Additionally, she serves on the advisory boards for Harvard Partners Healthcare Innovation, University of California Innovation Council, RAND Health Care and the U.K. National Health Services Digital Academy. Ms. Siegel co-chairs Stanford Medicine Board of Fellows, was a founding representative board member of NIH’s National Center for Advancing Translational Sciences and served on President Obama’s Precision Medicine Initiative Working Group. She is an Aspen Institute Henry Crown Fellow.